Selecta Biosciences Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. For more information about the company and updates, please visit https://www.cartesiantherapeutics.com/ or follow us on LinkedIn @Cartesian-Therapeutics.

✕

Access Insights for Selecta Biosciences and Millions of Other Companies

Sign up for full access to Selecta Biosciences information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory